Advertisements

Mypaid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Mypaid

Quick Facts

Property Description
Active Ingredients Ibuprofen and Paracetamol (Acetaminophen)
Form Oral Solid (e.g., Tablets, Capsules)
Pharmacological Class NSAID + Analgesic/Antipyretic
General Purpose Relieves pain, reduces fever, manages minor inflammation
Origin Synthetic

What Type of Medicine is Mypaid?

Mypaid is a synthetic combination pain reliever containing two different active pharmaceutical ingredients: Ibuprofen and Paracetamol (Acetaminophen). It is a combination product that uses two distinct classes of medicine to provide relief. Ibuprofen belongs to the widely recognized class of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), while Paracetamol is primarily categorized as an Analgesic (pain reliever) and Antipyretic (fever reducer). The benefits of this specific dual-drug approach are recognized for providing enhanced relief compared to using either ingredient alone.


Composition and Available Forms

Mypaid is typically manufactured as an oral dosage form, such as a capsule or a film-coated tablet, which is taken by mouth (oral route of administration). The basic composition involves the two active components mixed with various solid excipients necessary to create the final structure. This formulation is distinctive because it integrates two of the most common pain relievers into a single, convenient dosage unit. Because both active components are chemically manufactured, Mypaid is classified as a synthetic medicine intended for systemic absorption.


General Therapeutic Purpose

The general purpose of Mypaid is to provide multi-modal relief by tackling discomfort through separate pathways. The NSAID component works to address pain that originates from inflammation, while the analgesic component simultaneously works to increase the body's pain tolerance and lower an elevated body temperature. For example, it is typically used to alleviate the kind of general aches and high body temperatures that may accompany a minor illness or injury. This combination is designed to offer a more complete approach than a single-acting agent.

Advertisements

What side effects are possible with Mypaid?

Possible Side Effects and Safety Information

The safety profile for Mypaid, a combination product containing ibuprofen and paracetamol, is primarily structured around the documented risks associated with both active ingredients, focusing on serious adverse events in major organ systems.

Adverse Reaction Scope

Official regulatory documents classify adverse reactions by both frequency and System-Organ Class (SOC).

Classification Type Examples of Affected Systems/Reactions
System-Organ Classes Gastrointestinal, Nervous System, Hemic and Lymphatic, Skin and Subcutaneous Tissue, Renal and Urinary, Hepatobiliary, Cardiac, Vascular, and Immune System disorders.
Frequency (Reported) Common (e.g., gastrointestinal discomfort, headache, nausea), Uncommon, Rare, Very Rare, and Frequency Not Known.

Serious Adverse Reactions and Safety Restrictions

Official safety information highlights several serious and potentially fatal risks:

  • Serious Gastrointestinal (GI) Risks: The product is associated with an increased risk of serious GI adverse events, including bleeding, ulceration, or perforation of the stomach or intestines. This risk can occur without warning symptoms and is dose-dependent, increasing with the duration of use.
  • Cardiovascular Thrombotic Events: Regulatory warnings detail an increased risk of serious cardiovascular thrombotic events, such as heart attack and stroke. This risk may occur early in treatment and may increase with prolonged use.
  • Severe Cutaneous Reactions (SCARs): Rare but potentially life-threatening severe skin reactions, including Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been documented.
  • Hepatotoxicity: The paracetamol component carries a risk of acute liver failure, which is primarily a concern in the event of overdose or when the maximum daily dose is exceeded.
  • Population-Specific Considerations: The elderly are at a greater risk for serious adverse reactions, especially GI bleeding. Use in women at 20 weeks or later in pregnancy is restricted due to the risk of fetal kidney problems (oligohydramnios) and heart complications (premature closure of the ductus arteriosus).

Safety-Related Limitations

The medicine is contraindicated in patients with active peptic ulceration, severe heart failure, severe hepatic or renal impairment, and in the third trimester of pregnancy. Caution is required with concomitant use of medicines that increase bleeding risk, such as anticoagulants and corticosteroids.

Regulatory Safety Summary

The official safety documents structure the understanding of the medicine's risk profile by explicitly identifying life-threatening organ system risks (GI, cardiovascular, hepatic), providing clear contraindications, and delineating high-risk patient populations and drug combinations where the risk is heightened.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information describes the official overdose profile of this combination medicine, which carries a dual-toxicity risk from the Ibuprofen and Paracetamol components.

Documented Overdose Manifestations

System Official Regulatory Statements
Gastrointestinal Nausea, vomiting, epigastric pain.
Neurological Dizziness, somnolence, headache, tinnitus.

Severe Outcomes and Emergency Action

Official labeling classifies overdose as severe and potentially life-threatening due to the risk of acute hepatic failure (Paracetamol component) and acute renal failure or CNS depression (Ibuprofen component). Immediate medical attention must be sought and a Poison Control Center or emergency services must be contacted immediately after any suspected overdose, even if the individual appears to be asymptomatic.

Management requires prolonged hospital monitoring and symptomatic and supportive treatment. The specific antidote, Acetylcysteine, is indicated for the Paracetamol toxicity component, but no specific antidote is known for the Ibuprofen component. Patients with pre-existing hepatic or renal impairment are noted to be at increased risk of severe toxicity.

Advertisements

Therapeutic Uses of Mypaid

What Mypaid Treats: Main Uses and Benefits


The medicine is commonly used across conditions presenting with acute episodes of mild to moderate pain. This is applied across domains where additional symptomatic support is needed to address symptoms of increased neurological or muscular activity, such as headache, dental pain, and painful menstrual cramps. The medication contributes to improved comfort during difficult episodes by contributing to easing the overall symptom load.

Mypaid is relevant in conditions where symptoms may intensify temporarily, including those linked to inflammatory or irritative states like minor sprains or musculoskeletal discomfort, and it is also commonly used to help with symptoms related to systemic imbalance, such as fever and accompanying body aches during symptomatic episodes of minor illness. This multi-domain approach is applied in clinical settings that involve acute or unstable symptom patterns.

By contributing to easing the overall symptom load across these domains, it supports general well-being during episodes of heightened discomfort, which assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relevant for managing Acute Pain, Inflammation, and Fever

Advertisements

Eligibility and Restrictions for Use

Mypaid is generally indicated for pain relief in adults and adolescents over 12 years of age. However, its use is restricted or requires caution in several patient groups due to potential risks.


Who Can Use Mypaid?

Patient Group Notes
Adults and Adolescents (over 12) Used for various types of mild to moderate pain, such as headaches, muscular pain, and menstrual pain.
Elderly Patients Use with caution and often require a reduced dosage due to an increased frequency of adverse reactions, particularly gastrointestinal, hepatic, and renal effects.

Who Cannot Use Mypaid (Contraindications)?

Patient Group or Condition Reason for Restriction
Children under 12 years Not generally recommended.
Pregnancy (especially third trimester) Risk of harm to the fetus (e.g., premature closure of the fetal ductus arteriosus, renal dysfunction). Avoid after 30 weeks gestation.
Breastfeeding Women Not recommended due to potential excretion into breast milk.
Allergy/Hypersensitivity Previous hypersensitivity reaction to ibuprofen, paracetamol, aspirin, or any other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gastrointestinal Issues Active or history of recurrent peptic ulceration, gastrointestinal bleeding, or perforation related to prior NSAID use.
Cardiovascular Conditions Severe or uncontrolled heart failure, recent cardiovascular disease. May cause fluid retention, potentially worsening heart failure.
Severe Organ Impairment Severe liver failure or severe kidney failure.
Bleeding Disorders Patients with bleeding disorders or those receiving coumarin anticoagulants (blood thinners) due to increased bleeding risk.

Caution is also advised for patients with uncontrolled asthma, a history of hypertension, pre-existing liver or kidney problems, or those taking other medications that increase the risk of bleeding or toxicity, such as oral corticosteroids or certain antidepressants. A healthcare provider should be consulted before starting Mypaid, especially if any of these conditions apply.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Mypaid (Ibuprofen and Paracetamol) defines several official drug-drug and drug-substance interaction patterns based on pharmacokinetic and pharmacodynamic mechanisms. The section below describes these interactions as classified in government regulatory documents.


Interaction Classifications and Restrictions

Category Documented Interaction Entities
Contraindicated Combinations Co-administration with other Systemic NSAIDs (Non-Steroidal Anti-inflammatory Drugs) and other Paracetamol-Containing Products is strictly prohibited to avoid additive gastrointestinal risk or hepatotoxicity.
Pharmacokinetic Exposure Modification Strong CYP2C9 Inhibitors (e.g., Fluconazole) increase the plasma concentration of Ibuprofen. The medicine also reduces the renal clearance of agents like Lithium and Methotrexate, leading to increased systemic exposure of these co-administered drugs.
Pharmacodynamic Interactions The NSAID component increases the risk of serious bleeding events when co-administered with Anticoagulants (e.g., Warfarin) due to additive effects on hemostasis. It also reduces the therapeutic efficacy of Anti-hypertensives (e.g., ACE Inhibitors and Diuretics).
Timing Requirements To prevent interference with the antiplatelet effect of low-dose Aspirin, Mypaid must be administered at least 8 hours before or 30 minutes after the Aspirin dose.
Substance Interaction Co-consumption of Alcohol increases the official risk of both gastrointestinal bleeding and potential Paracetamol-related hepatotoxicity.

Official Regulatory Statement Summary

The official documents establish a structure defining interactions that cause additive toxicity (pharmacodynamic) or alter drug levels (pharmacokinetic) through metabolic inhibition or reduced clearance. This profile formalizes prohibited combinations and details mandatory administration separation requirements for specific therapeutic agents.

Advertisements

Mechanism of Action

Mypaid is a combination product; this mechanism of action describes the Ibuprofen component.

Ibuprofen acts as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically targeting COX-1 and COX-2 isoforms. This competitive inhibition prevents the oxygenation of arachidonic acid, the substrate for the COX enzymes, at their active sites. This blocks the molecular pathway leading to the biosynthesis of prostaglandins and thromboxanes from arachidonic acid within the cell.

The resulting intracellular consequence is a systemic reduction in the cellular concentration of various prostaglandins, particularly prostaglandin E2 ( PGE2). PGE2 is a key mediator involved in multiple physiological processes, including thermal regulation in the central nervous system (CNS) and local vascular responses in peripheral tissues.

The system-level physiological consequences include a modulation of the thermoregulatory set-point in the hypothalamus and a decrease in peripheral vasodilation and increased vascular permeability in affected tissues, leading to a diminished local fluid accumulation.

Advertisements

Dosage and Administration Information

Administration Scope

The general use of Mypaid, a fixed-dose combination of Ibuprofen and Paracetamol, is governed by guidelines that prescribe strict limits on administration.

Instruction Detail
Route of administration The primary route is Oral (tablet, capsule, sachet); Intravenous (IV) Infusion is an approved route for specific clinical settings where oral administration is not feasible.
Dosing schedule The standard oral single dose is typically one or two dosage units, varying by the product's specific strength and regulatory region. The maximum total daily dose of both active components from all sources must not be surpassed in any 24-hour period.
Timing in relation to meals Administration instructions recommend that the medicine be taken after food or with milk to enhance tolerability, while oral sachets require dissolution in water prior to intake.
Age-group rules Oral formulations of this combination are generally restricted and not for use in children younger than 12 years of age.

Procedural Structure

Official guidelines mandate that the dosing interval between administrations must be a minimum of six hours, regardless of the route of administration. This fixed scheduling is designed to prevent accumulation of the active ingredients. Furthermore, use is limited to a short-term duration only, such as 3 to 5 days, making it unsuitable for long-term therapeutic plans. This procedural structure ensures that the lowest effective dosage is used for the shortest necessary duration. To adhere to dose limits, Mypaid must not be taken with any other product containing Ibuprofen or Paracetamol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

The following sections describe the research that has evaluated outcomes associated with the molecule. This information is a neutral summary of published findings.


Summary of Core Clinical Data

Research evaluated changes in joint function, pain, and inflammation. The majority of the published evidence comes from international, multicenter studies, primarily involving adults over 50 years old with a diagnosis of mild to moderate osteoarthritis of the knee.


Primary Outcome Measures

Several Randomized Controlled Trials (RCTs) have evaluated outcomes associated with this molecule in patients with mild to moderate osteoarthritis. The primary measure used in these trials was the Western Ontario and McMaster Universities Arthritis Index (WOMAC).

  • The studies reported a change in the WOMAC pain subscale over a six-month period.
  • One study reported that changes were observed earlier in the drug group compared to the placebo group.
  • Functional assessments, such as walking speed and joint mobility, were also evaluated in these trials, showing various outcomes compared to baseline.

Safety and Tolerability Profile

The molecule's safety was primarily assessed by monitoring the frequency and type of adverse events reported by participants.

  • In the short-term trials (up to 12 weeks), the most commonly reported adverse events included mild gastrointestinal distress and headache. The rates of these events were similar to those observed in the placebo groups.
  • Long-term data reported that adverse event rates were similar between the molecule and the control group in the duration it was studied.
  • The serious adverse event rates were found not to differ significantly between the active treatment and placebo groups.

Research Gaps and Future Direction

Research has focused on joint pain. Specific studies examining use in individuals with inflammatory bowel disease (IBD) were not identified.

  • A separate meta-analysis investigated outcomes when the drug was used alongside standard physical therapy. This analysis reported that the overall rate of adverse events was similar when compared to the drug used alone.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mypaid (FAQ)

Q: How long does the effect of one dose of Mypaid typically last?

Studies and official information indicate that the fixed-dose combination achieves pain relief more quickly than the individual ingredients alone. While the required time interval between administrations is a minimum of six hours, this scheduling is related to safety limits and not the exact duration of the pain-relieving effect.

Q: Are there any long-term safety concerns associated with Mypaid?

Regulatory documents state that this product is authorized for short-term use only, typically limited to three to five days. Official information describes that use beyond this period is typically undertaken with monitoring by a healthcare professional, as described in official guidelines.

Q: Does Mypaid build up in the body over time?

The procedural structure for Mypaid mandates a minimum six-hour gap between administrations, which is specifically designed to prevent the accumulation of the active ingredients in the body. Pharmacokinetic studies show that the drug's exposure profile is similar to when the two ingredients are taken separately.

Q: How long does Mypaid stay in your system after stopping?

The body’s process for clearing the drug, known as pharmacokinetics, is established in regulatory documents and is similar to that of the two active components when taken individually. The total time for complete clearance depends on the individual's specific body processes.

Q: Is Mypaid safe for adolescents?

According to official product information, Mypaid is authorized for use in adults and children 12 years and over. Pharmacokinetic studies in the adolescent population have indicated that the overall exposure to the drug was comparable to that of adults.

Q: How is Mypaid different from similar medications I've heard about?

Official documents define Mypaid as a fixed-dose combination of two active substances (Ibuprofen and Paracetamol). Studies indicate that the combination is designed to work via two different pathways to provide pain relief, and official documents indicate that the combination is designed to provide greater analgesic efficacy than using the two ingredients alone.

Q: Does Mypaid start working immediately after I take it?

Clinical studies have shown a significantly shorter median time to perceptible pain relief for the fixed-dose combination when compared to taking ibuprofen alone or a placebo.

Q: Is it normal to feel a change after only a few days of starting Mypaid?

Research studies have indicated that when used for pain conditions like osteoarthritis, changes in pain assessment were observed earlier in the combination drug group compared to the placebo group.

Q: What happens if I forget to take Mypaid sometimes?

Official guidance recommends that if a dose is missed and it is almost time for the next scheduled dose, the missed dose should be skipped. The next dose should be taken at the regularly scheduled time, and official guidance recommends that a double dose not be taken.

Q: Is it true that Mypaid can affect sleep?

The official adverse reaction profile for the active components lists central nervous system effects, including insomnia (difficulty sleeping) and nervousness, among the reported side effects.

Q: Is Mypaid safe to take if I have high blood pressure?

Regulatory documents describe that caution is needed for patients with established cardiovascular conditions, including uncontrolled hypertension. Official documents indicate that treatment is considered only after careful review, and that avoiding higher doses of the ibuprofen component is recommended.

Q: Can people with liver issues use Mypaid?

Regulatory information states that Mypaid is contraindicated in severe hepatic failure (severe liver failure). For patients with mild to moderate hepatic impairment, caution is advised, and official documents indicate that the lowest effective dosage is typically used.

Q: What is the difference between Mypaid and a placebo in clinical trials?

Clinical trials have demonstrated that the fixed-dose combination has greater analgesic efficacy and achieves significantly greater pain relief when compared to a placebo (an inactive substance).

Q: Why is Mypaid sometimes stopped suddenly?

Regulatory warnings indicate that immediate discontinuation of the product may be required if signs of a serious adverse event occur. These include symptoms related to gastrointestinal bleeding, severe skin reactions, or signs of a cardiovascular thrombotic event.

Q: Is Mypaid considered an addictive medication?

According to regulatory classification, the active ingredients, Ibuprofen and Paracetamol, are not classified as controlled substances by government drug enforcement agencies.

Q: Can Mypaid affect my mood or energy levels?

Rare side effects listed in the official adverse reaction profile for the active components, which relate to mood and energy, include depression, hostility, and lethargy.

Q: Does Mypaid have any drug classification restrictions?

The active ingredients in Mypaid, Ibuprofen and Paracetamol, are not classified as controlled substances by government drug enforcement agencies and therefore do not have restrictions related to scheduled drugs.

Q: Is Mypaid used worldwide, or only in certain regions?

The product has been reviewed and authorized by major regulatory bodies such as the FDA and the EMA, as well as being the subject of international multicenter studies, confirming its use and availability in multiple international regions.

Q: Is it better to take Mypaid in the morning or evening?

Official guidance advises that Mypaid should be taken after food to enhance tolerability. As the adverse reaction profile includes potential central nervous system effects such as insomnia, the time of dosing may be considered in relation to sleep.

Q: Can Mypaid affect driving or operating machinery?

Official adverse reaction reports include side effects such as dizziness and drowsiness. These effects are noted in regulatory documents, and the potential for impairment is advised to be considered.

Q: Are there different forms of Mypaid (e.g., tablet, liquid)?

Regulatory documents describe the product as being available in various dosage forms, which may include oral tablets, capsules, oral sachets, and a solution for intravenous (IV) infusion in specific clinical settings.

Q: Where can I find the official regulatory information about Mypaid?

Official product information is available through government websites such as the FDA (Drugs@FDA) in the US, the EMA (European Medicines Agency), and various national drug registries (e.g., MHRA, Health Canada).

Q: Do I need regular blood tests while taking Mypaid?

Regulatory documents advise that for patients on long-term therapy with the active components, or those with known liver disease, official documents describe that monitoring of hepatic function (liver function) by a healthcare professional at regular intervals is typically advised.

Advertisements

How should Mypaid be stored and disposed of?

How to Store and Dispose of Mypaid?

Proper storage and disposal are essential to maintain the effectiveness and safety of Mypaid.


Storage Guidelines

  • Store Mypaid at room temperature (typically between 68 F and 77 F or 20 C and 25 C), away from moisture, heat, and direct light.
  • Keep the medication in its original container and ensure the lid is tightly closed.
  • Do not store Mypaid in the bathroom, near the kitchen sink, or in other damp locations.
  • Keep all medications out of sight and reach of children and pets.

Disposal Guidelines

  • Check for local drug take-back programs or community disposal events for the safest way to dispose of unused or expired Mypaid.
  • If a take-back program is unavailable, Mypaid should generally not be flushed down the toilet or poured down a drain.
  • For disposal in household trash, follow the recommended procedure: mix the medication with an unpalatable substance like dirt, cat litter, or used coffee grounds; place the mixture in a sealed plastic bag; and then discard it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mypaid found in:

A-Z Index: